Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study

被引：2

作者：

Furubayashi, Nobuki ^{[1
]}

Morokuma, Futoshi ^{[2
]}

Tomoda, Toshihisa ^{[3
]}

Hori, Yoshifumi ^{[4
]}

Negishi, Takahito ^{[1
]}

Miura, Akihiro ^{[1
]}

Komori, Hiroki ^{[1
]}

Kuroiwa, Kentaro ^{[4
]}

Nakamura, Motonobu ^{[1
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept Urol, Fukuoka, Japan

[2] Saga Ken Med Ctr Koseikan, Dept Urol, Saga, Japan

[3] Oita Prefectural Hosp, Dept Urol, Oita, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Dept Urol, Miyazaki, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 03期

关键词：

chemotherapy pembrolizumab; real -world clinical practice; Advanced urothelial carcinoma; platinum-based; IMMUNE CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; GEMCITABINE; CARBOPLATIN; CISPLATIN; CANCER; TUMORS; CELLS;

D O I：

10.21873/anticanres.15631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear. Patients and Methods: Thirty-four patients who received pembrolizumab as second-line treatment after firstline platinum-based chemotherapy were retrospectively evaluated. Results: According to overall survival (OS) from pembrolizumab, there was a significant difference between <= 4 and 0.001), but not between <= 6 and 6 cycles (18.6 and 27.3 months, p=0.276). Conclusion: The optimal timing of switching from platinum-base chemotherapy to pembrolizumab in advanced UC is around six cycles.

引用

页码：1571 / 1577

页数：7

共 50 条

[21] Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study
Tohru Nakagawa
Yoshimitsu Komemushi
Taketo Kawai
Masafumi Otsuka
Jimpei Miyakawa
Yukari Uemura
Atsushi Kanatani
Satoru Taguchi
Akihiro Naito
Motofumi Suzuki
Hiroaki Nishimatsu
Yoshikazu Hirano
Yoshinori Tanaka
Akihiko Matsumoto
Hideyo Miyazaki
Tetsuya Fujimura
Hiroshi Fukuhara
Haruki Kume
Yasuhiko Igawa
Yukio Homma
World Journal of Urology, 2017, 35 : 1569 - 1575
[22] Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study
Nakagawa, Tohru
Komemushi, Yoshimitsu
Kawai, Taketo
Otsuka, Masafumi
Miyakawa, Jimpei
Uemura, Yukari
Kanatani, Atsushi
Taguchi, Satoru
Naito, Akihiro
Suzuki, Motofumi
Nishimatsu, Hiroaki
Hirano, Yoshikazu
Tanaka, Yoshinori
Matsumoto, Akihiko
Miyazaki, Hideyo
Fujimura, Tetsuya
Fukuhara, Hiroshi
Kume, Haruki
Igawa, Yasuhiko
Homma, Yukio
WORLD JOURNAL OF UROLOGY, 2017, 35 (10) : 1569 - 1575
[23] Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Rizzo, Mimma
Soares, Andrey
Grande, Enrique
Bamias, Aristotelis
Kopp, Ray Manneh
Lenci, Edoardo
Buttner, Thomas
Salah, Samer
Grillone, Francesco
de Carvalho, Icaro Thiago
Tapia, Jose Carlos
Gucciardino, Calogero
Pinto, Alvaro
Mennitto, Alessia
Abahssain, Halima
Rescigno, Pasquale
Myint, Zin
Takeshita, Hideki
Spinelli, Gian Paolo
Popovic, Lazar
Vitale, Maria Giuseppa
Fiala, Ondrej
Giannatempo, Patrizia
Zakopoulou, Roubini
Carrozza, Francesco
Massari, Francesco
Monteiro, Fernando Sabino Marques
Pace, Maria Paola
Giannini, Massimo
Roviello, Giandomenico
Porta, Camillo
Battelli, Nicola
Kanesvaran, Ravindran
Santoni, Matteo
SCIENTIFIC REPORTS, 2024, 14 (01):
[24] Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort
Prendergast, Emily N.
Holzapfel, Marie
Mueller, Jennifer J.
Leitao, Mario M., Jr.
Gunderson, Camille C.
Moore, Kathleen N.
Erickson, Britt K.
Leath, Charles A., III
Moore, Elena S. Diaz
Cohen, Joshua G.
Walsh, Christine S.
GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 274 - 278
[25] Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma
Hosogoe, Shogo
Hatakeyama, Shingo
Kusaka, Ayumu
Hamano, Itsuto
Iwamura, Hiromichi
Fujita, Naoki
Yamamoto, Hayato
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Ohyama, Chikara
EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 946 - 953
[26] Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Rizzo, Alessandro
Buti, Sebastiano
Giannatempo, Patrizia
Salah, Samer
Molina-Cerrillo, Javier
Massari, Francesco
Kopp, Ray Manneh
Fiala, Ondrej
Galli, Luca
Myint, Zin W.
Tural, Deniz
Soares, Andrey
Pichler, Renate
Mennitto, Alessia
Abahssain, Halima
Calabro, Fabio
Monteiro, Fernando Sabino M.
Albano, Anna
Mollica, Veronica
Giudice, Giulia Claire
Takeshita, Hideki
Santoni, Matteo
CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (05) : 655 - 665
[27] Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area
Yu, Yahui
Liang, Hu
Lv, Xing
Ke, Liangru
Qiu, Wenze
Huang, Xinjun
Liu, Guoying
Li, Wangzhong
Guo, Xiang
Xiang, Yanqun
Xia, Weixiong
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (11) : 2231 - 2243
[28] The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma
Okita, Kazutaka
Hatakeyama, Shingo
Hagiwara, Kazuhisa
Suzuki, Yuichiro
Tanaka, Toshikazu
Noro, Daisuke
Tokui, Noriko
Fujita, Naoki
Konishi, Sakae
Okamoto, Teppei
Yoneyama, Tohru
Yamamoto, Hayato
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Ohyama, Chikara
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (12) : 832.e17 - 832.e23
[29] PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
Huang, Zhe
Zhou, Chunhua
Xiong, Yi
Yang, Feng
Zeng, Fanxu
Jiang, Wenjuan
Zhang, Yongchang
Yang, Haiyan
Liu, Li
Zeng, Liang
Yang, Nong
Wang, Zhan
FRONTIERS IN ONCOLOGY, 2022, 12
[30] Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
Houede, N.
Locker, G.
Lucas, C.
Parra, H. Soto
Basso, U.
Spaeth, D.
Tambaro, R.
Basterretxea, L.
Morelli, F.
Theodore, C.
Lusuardi, L.
Lainez, N.
Guillot, A.
Tonini, G.
Bielle, J.
Del Muro, X. Garcia
BMC CANCER, 2016, 16

← 1 2 3 4 5 →